TY - JOUR
TI - Pharmacotherapeutic advances for recurrent urinary tract infections in women
AU - Moussa, M.
AU - Abou Chakra, M.
AU - Dellis, A.
AU - Moussa, Y.
AU - Papatsoris, A.
JO - Expert Opinion on Pharmacotherapy
PY - 2020
VL - null
TODO - null
SP - null
PB - Taylor and Francis Ltd.
SN - 1465-6566, 1744-7666
TODO - 10.1080/14656566.2020.1795128
TODO - antiinfective agent;  avibactam, ceftazidime drug combination;  azabicyclo derivative;  ceftazidime;  ceftolozane, tazobactam drug combination;  cephalosporin derivative;  fosfomycin;  tazobactam, beverage;  chemistry;  cranberry;  drug combination;  female;  human;  microbiology;  recurrent disease;  secondary prevention;  urinary tract infection, Anti-Bacterial Agents;  Azabicyclo Compounds;  Beverages;  Ceftazidime;  Cephalosporins;  Drug Combinations;  Female;  Fosfomycin;  Humans;  Recurrence;  Secondary Prevention;  Tazobactam;  Urinary Tract Infections;  Vaccinium macrocarpon
TODO - Introduction: Treatment of recurrent Urinary tract infections (UTIs) has become challenging because of the dramatic increase in the rates of recurrent infection andof multidrug-resistant (MDR) infections. Areas covered: The authors review recurrent UTIs(rUTI) management in women. Expert opinion: Continuous or post-coital prophylaxis with low-dose antimicrobials or intermittent self-treatment has all been demonstrated to be effective in managing rUTIs in women. Intravaginal estrogen therapy, shows potential toward preventing rUTI. Oral vaccine Uro-Vaxom seems to reduce the number of UTIs. There is evidence that other therapies (e.g. cranberry, Methenamine hippurate, oral D-mannose) may decrease the number of symptomatic UTIs. The treatment of CRE-UTIs is focused on a colistin backbone. Carbapenems are considered first-line agents for UTIs caused by ESBL, but their use is associated with increased MDR. The usage of non-carbapenem for the treatment of ESBL UTIs is necessary. Cefepime, Piperacillin-Tazobactam, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam are justified options. Oral therapy with Pivmecillinam, Fosfomycin, and Nitrofurantoin can be used against uncomplicated UTIs due to ESBL infection. © 2020 Informa UK Limited, trading as Taylor & Francis Group.
ER -